NURIX THERAPEUTICS, INC. (NRIX) Spending and interest coverage
- R&D / revenue · 12 months: Value 927.31%; Formula and calculation Research and development expense / revenue. Period ending 2026-05-31..
- Stock-based compensation / revenue · 12 months: Value 107.84%; Formula and calculation Share-based compensation / revenue. Period ending 2026-05-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 927.31% | Research and development expense / revenue. Period ending 2026-05-31. $340.93M ÷ $36.77M × 100 ≈ 927.31% |
| Stock-based compensation / revenue · 12 months | 107.84% | Share-based compensation / revenue. Period ending 2026-05-31. $39.65M ÷ $36.77M × 100 ≈ 107.84% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 340.93M USD | Research and Development Expense |
| Revenue | 36.77M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 39.65M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -361.18M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $340.93M | $36.77M | $39.65M | $-361.18M | (m) | 927.31% | 107.84% | (m) | (m) |
| 2026-02-28 | $331.38M | $71.78M | $38.65M | $-315.30M | (m) | 461.66% | 53.84% | (m) | (m) |
| 2025-11-30 | $316.90M | $83.98M | $37.97M | $-285.67M | (m) | 377.36% | 45.21% | (m) | (m) |
| 2025-08-31 | $301.10M | $83.69M | $37.39M | $-267.23M | (m) | 359.80% | 44.67% | (m) | (m) |
| 2025-05-31 | $270.46M | $88.38M | $36.37M | $-230.45M | (m) | 306.02% | 41.15% | (m) | (m) |
| 2025-02-28 | $241.29M | $56.42M | $34.83M | $-230.67M | (m) | 427.69% | 61.73% | (m) | (m) |
| 2024-11-30 | $221.63M | $54.55M | $33.93M | $-213.03M | (m) | 406.30% | 62.20% | (m) | (m) |
| 2024-08-31 | $204.12M | $56.42M | $33.45M | $-193.70M | (m) | 361.76% | 59.27% | (m) | (m) |
| 2024-05-31 | $196.50M | $62.30M | $33.14M | $-179.10M | (m) | 315.39% | 53.19% | (m) | (m) |
| 2024-02-29 | $193.34M | $80.89M | $33.01M | $-157.33M | (m) | 239.02% | 40.81% | (m) | (m) |
| 2023-11-30 | $189.15M | $76.99M | $33.67M | $-155.06M | (m) | 245.69% | 43.74% | (m) | (m) |
| 2023-08-31 | $185.54M | $68.61M | $33.95M | $-158.42M | (m) | 270.42% | 49.48% | (m) | (m) |
| 2023-05-31 | $185.45M | $60.94M | $32.49M | $-165.13M | (m) | 304.33% | 53.32% | (m) | (m) |
| 2023-02-28 | $187.18M | $41.69M | $30.54M | $-184.07M | (m) | 448.96% | 73.26% | (m) | (m) |
| 2022-11-30 | $184.50M | $38.63M | $28.13M | $-183.87M | (m) | 477.64% | 72.83% | (m) | (m) |
| 2022-08-31 | $174.92M | $39.24M | $24.68M | $-173.13M | (m) | 445.77% | 62.89% | (m) | (m) |
| 2022-05-31 | $158.07M | $38.70M | $22.00M | $-155.41M | (m) | 408.43% | 56.85% | (m) | (m) |
| 2022-02-28 | $136.57M | $34.36M | $19.17M | $-136.11M | (m) | 397.46% | 55.79% | (m) | (m) |
| 2021-11-30 | $116.43M | $29.75M | $15.80M | $-117.89M | (m) | 391.37% | 53.11% | (m) | (m) |
| 2021-08-31 | $100.35M | $29.04M | $13.49M | $-99.94M | (m) | 345.52% | 46.46% | (m) | (m) |
| 2021-05-31 | $88.38M | $22.88M | $10.29M | $-90.14M | (m) | 386.35% | 45.00% | (m) | (m) |
| 2021-02-28 | $76.53M | $19.97M | $6.83M | $-76.95M | (m) | 383.28% | 34.18% | (m) | (m) |
| 2020-11-30 | $66.49M | $17.82M | $4.30M | $-64.98M | (m) | 373.14% | 24.14% | (m) | (m) |
| 2020-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-05-31 | (m) | $19.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-02-29 | (m) | $24.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-11-30 | $45.02M | $31.11M | $510.00K | $-22.24M | (m) | 144.71% | 1.64% | (m) | (m) |
| 2019-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |